Table 1.

Proteins that affect proliferation in neuroblastoma through transcription and their targeted drugs. Mechanism of action and stage of development in neuroblastoma is listed along with references.

Target Protein	Drug	Mechanism of Action	Stage of Development	References
SULF-2	siSULF-2	Double-stranded RNA that cleaves SULF-2 mRNA	In vitro	[25]
N-MYC	siMYCN	Double-stranded RNA that cleaves MYCN mRNA	In vitro	[27]
	PNA	Synthetic polymer that binds MYCN DNA to inhibit N-MYC expression	In vitro	[28]
	miRNAs	Single-stranded RNA that inhibits translation of MYCN mRNA	In vitro	[29]
	JQ1	Inhibits BET bromodomains	In vivo	[30]
	I-BET762	Inhibits BET bromodomains	In vivo	[31]
	OTX015	Inhibits BET bromodomains	Clinical trial	[32]
	10058-F4	Inhibits N-MYC/MAX dimerization	In vivo	[34]
NFκB	Bortezomib	Inhibits proteasomal degradation of IκB, thus deactivating NFκB	Clinical trial	[40,41,42,43,44]
	Curcumin	Inhibits activation of NFκB	In vivo	[47]
	Oleanolic acid derivatives (CDDO-Im and CDDO-Me)	Inhibit TNFα-induced targeting of NFκB to the nucleus	In vivo	[48,49]
MDM2	Nutlin-3	Releases P53 from negative control by MDM2	In vivo	[64]
	MI-63	Releases P53 from negative control by MDM2	In vitro	[65]